Effects of pargyline on cellular proliferation in human breast cancer cells

Lee, Hyung Tae; Jung, Kyoung Hwa; Kim, Se Kye; Choi, Mi Ran; Chai, Young Gyu

doi:10.1007/s13273-012-0048-y

Cited by 9 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efficacy of pargyline to inhibit the growth of breast cancer cells has also been described (Lee et al, 2012). At this point it is not clear whether MAO-B inhibitors have significant effects in tumor growth inhibition or whether the effect as described for pargyline has been evoked by interacting with MAO-A and MAO-B concomitantly.…”

Section: Other Diseasesmentioning

confidence: 99%

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Entzeroth¹,

Ratty²

2017

OJD

View full text Add to dashboard Cite

Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depression, they became less a therapeutic choice for the physicians mostly due to severe side effects, such as liver failure and hypertensive crisis associated specifically with the first generation of inhibitors. Nevertheless, this class of drugs is still being used for treatment specifically as more selective and reversible inhibitors became available and will provide clinicians with additional treatment options. The current review revisits monoamine oxidase inhibitors and their potential in the treatment of human diseases, such as anxiety, depression, mood and personality disorders, and pain and introduces current ideas and developments.

show abstract

Section: Other Diseasesmentioning

confidence: 99%

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Entzeroth¹,

Ratty²

2017

OJD

View full text Add to dashboard Cite

show abstract

“…LSD1 inhibitors prevent the removal of mono-and dimethyl-lysine but not trimethyl-lysine due to the mechanism of the enzyme (see Figure 3). Irreversible MAO inhibitors tranylcypromine 29, ( Figure 9A) pargyline 30, and phenelzine 31, have LSD1 inhibitory activity [152,153] and are being used as lead compounds to generate potent and selective LSD1 inhibitors especially for acute myeloid leukemia [154]. This has led to the production of bizine 32, an LSD1 selective inhibitor analogue of 31, capable of modulating bulk histone methylation in cancer cells [155].…”

Section: Lysine Demethylase Inhibitorsmentioning

confidence: 99%

Inhibitors of Enzymes Catalyzing Modifications to Histone Lysine Residues: Structure, Function and Activity

et al. 2016

View full text Add to dashboard Cite

Gene expression is partly controlled by epigenetic mechanisms including histone-modifying enzymes. Some diseases are caused by changes in gene expression that can be mitigated by inhibiting histone-modifying enzymes. This review covers the enzyme inhibitors targeting histone lysine modifications. We summarize the enzymatic mechanisms of histone lysine acetylation, deacetylation, methylation and demethylation and discuss the biochemical roles of these modifications in gene expression and in disease. We discuss inhibitors of lysine acetylation, deacetylation, methylation and demethylation defining their structure-activity relationships and their potential mechanisms. We show that there are potentially indiscriminant off-target effects on gene expression even with the use of selective epigenetic enzyme inhibitors.

show abstract

“…Cortez et al (13) reported that after human breast cancer cells were injected into nude mice, regular treatment of pargyline exhibited suppression of tumor growth. Based on these previous studies (11–16), MAO inhibitors may have potential as anticancer agents.…”

Section: Introductionmentioning

confidence: 95%

“…Tranylcypromine, clorgyline and pargyline effectively decreased cell proliferation in various breast cancer cell lines such as MDA-MB-231, MDA-MB-453, MCF-7 and T47D (11,16). Also, in neuroblastoma cells, tranylcypromine showed similar results with breast cancer cells (12).…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies have reported that various monoamine oxidase (MAO) inhibitors including pargyline, tranylcypromine, clorgyline and other derivatives are used for cancer treatment in human cancer cells (11–16). Tranylcypromine, clorgyline and pargyline effectively decreased cell proliferation in various breast cancer cell lines such as MDA-MB-231, MDA-MB-453, MCF-7 and T47D (11,16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells

et al. 2013

Self Cite

View full text Add to dashboard Cite

Chemotherapy is one of the therapeutic strategies that has been used for the inhibition of cancer cell proliferation in several types of cancer, including prostate cancer. Although monoamine oxidase (MAO) inhibitors, phytoestrogen and antioxidants used in chemotherapy have been systematically studied, their effects on cancer cell growth remain to be fully understood. The purpose of this study was to investigate the effects of the MAO inhibitors, pargyline and tranylcypromine on cell survival in human prostate carcinoma (LNCaP-LN3) cells. After treating LNCaP-LN3 cells with pargyline or tranylcypromine, we examined cell proliferation, cell cycle pattern, apoptosis and the expression levels of apoptosis-related genes. The proliferation of cells exposed to pargyline decreased in a dose- and time-dependent manner, while tranylcypromine-treated cells showed the opposite results. Treatment with pargyline significantly induced cell cycle arrest at the G1 phase compared to the control and tranylcypromine-treated cells. In addition, pargyline induced an increase in the cell death rate by promoting apoptosis; however, tranylcypromine had no effect on LNCaP-LN3 cells. Based on our results, we suggest that pargyline is more powerful than tranylcypromine for the treatment of human prostate cancer.

show abstract

Effects of pargyline on cellular proliferation in human breast cancer cells

Cited by 9 publications

References 32 publications

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Inhibitors of Enzymes Catalyzing Modifications to Histone Lysine Residues: Structure, Function and Activity

Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells

Contact Info

Product

Resources

About